Finally, Allergan is now also a big player, after having spent nearly $2 billion on acquiring two biotech firms in 2016, Tobira and Akarna. It now aims to run trials of Tobira’s cenicriviroc (a ...

The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...